GlaxoSmithKline said recently it was preparing to launch a Phase III study of mepolizumab in fighting severe hypereosinophilic syndrome.
According to the American Academy of Allergy Asthma and Immunology, severe hypereosinophilic syndrome occurs when people have significantly more eosinophils, types of white blood cells that are vital in a person's immune system, than they need. Eosinophils in the bloodstream can infiltrate tissues and cause inflammation and organ damage, GlaxoSmithKline said in a release.
GlaxoSmithKline said its study will add mepolizumab to the therapy of those fighting the blood disorder. GlaxoSmithKline said it hopes to choose 80 to 120 people fighting the condition for the study. The only criterion for being part of the test will be that people fighting the condition will have had at least two instances in the past year where the symptoms they dealt with progressed to the point where they needed more treatment.